CINGW — Cingulate Inc. Warrants
NASDAQ
$0.01
-$0.00 (-30.70%)
Cingulate Inc. Warrants (CINGW) common stock listed on NASDAQ. It is led by Shane J. Schaffer Pharm.D., based in 1901 West 47th Place, Kansas City, KS, United States, 66205, with about 14 employees. Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Net income was -$7.3M.
Use this CINGW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CINGW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CINGW SEC filings page. Lician reads the product cache first so this HTML stays unique to Cingulate Inc. Warrants even when a live quote feed is slow.
About Cingulate Inc. Warrants
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
CINGW Key Statistics
Market Cap
$0.00M
Volume
6,003
Previous Close
$0.01
Day Range
$0.01 – $0.01
EPS
-$10.20
Revenue
$0.00
Net Income
-$15.55M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
14
CINGW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$15.55M | -$23.53M | -$17.68M | -$20.71M |
| EPS (Diluted) | -$10.20 | -$311.99 | -$29.35 | $0.00 |
Total Assets
$14.86M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$12.21M
Operating Cash Flow
-$18.45M
Free Cash Flow
$0.00
Cingulate Inc. Warrants Company Information
- Co-Founder, CEO & Director
- Shane J. Schaffer Pharm.D.
- Headquarters
- 1901 West 47th Place, Kansas City, KS, United States, 66205
- Website
- www.cingulate.com
- Phone
- 913 942 2300
- IPO / Founded
- 2021-12-08